China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294

Watchlist Manager
China Resources Boya Bio pharmaceutical Group Co Ltd Logo
China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
Watchlist
Price: 31.3 CNY -2.43% Market Closed
Market Cap: 15.8B CNY
Have any thoughts about
China Resources Boya Bio pharmaceutical Group Co Ltd?
Write Note

Discount Rate

Cost of Equity
Discount Rate

6.53%
Cost of Equity
2.1%
Risk-Free Rate
1.09
Beta
4.06%
ERP

China Resources Boya Bio pharmaceutical Group Co Ltd's Cost of Equity, calculated using the formula Risk-Free Rate + Beta x ERP, stands at 6.53%. The Beta, indicating the stock's volatility relative to the market, is 1.09, while the current Risk-Free Rate, based on government bond yields, is 2.1%, and the ERP, measuring the extra return over the risk-free rate required by investors, is 4.06%.

Loading Cost of Equity History...

WACC
Discount Rate

6.52%
WACC
0.45%
Debt Weight
5%
Cost of Debt
6.53%
Cost of Equity

China Resources Boya Bio pharmaceutical Group Co Ltd's Weighted Average Cost of Capital (WACC) is calculated as the weighted average of its cost of equity and cost of debt, adjusted for tax. The WACC stands at 6.52%. This includes the cost of equity at 6.53%, calculated as Risk-Free Rate + Beta x ERP, and the cost of debt at 5%, reflecting the interest rate on China Resources Boya Bio pharmaceutical Group Co Ltd's debt adjusted for tax benefits. The weight of debt in the capital structure is 0.45%.

Loading WACC History...

What is China Resources Boya Bio pharmaceutical Group Co Ltd's discount rate?

China Resources Boya Bio pharmaceutical Group Co Ltd 's current Cost of Equity is 6.53%, while its WACC stands at 6.52%. The selection of the appropriate discount rate is contingent on the type of cash flows being discounted.

For Equity Valuation: When valuing equity, especially in scenarios where you are discounting cash flows to equity holders (such as Net Income, Earnings Per Share (EPS), or Free Cash Flow to Equity), the Cost of Equity should be used.

For Firm Valuation: In contrast, when valuing the entire firm and discounting cash flows available to both debt and equity holders (like Free Cash Flow to the Firm), the Weighted Average Cost of Capital (WACC) is the appropriate rate."

How is Cost of Equity for China Resources Boya Bio pharmaceutical Group Co Ltd calculated?

The Cost of Equity represents the return a company must offer investors to compensate for the risk of investing in its stock. It's calculated using the Capital Asset Pricing Model (CAPM), which combines the risk-free rate, the stock's beta, and the equity risk premium (ERP).

This model considers the inherent risk of investing in the stock compared to a risk-free investment and the market's overall risk.

Here is how we calculate the cost of equity for China Resources Boya Bio pharmaceutical Group Co Ltd

Cost of Equity
6.53%
=
Risk-Free Rate
2.1%
+
Beta
1.09
x
ERP
4.06%

How is WACC for China Resources Boya Bio pharmaceutical Group Co Ltd calculated?

WACC, or Weighted Average Cost of Capital, is a calculation that reflects the average rate of return a company is expected to pay its security holders to finance its assets. It is a critical measure in financial analysis for valuing a company’s entire operations.

The WACC formula combines the costs of equity and debt, weighted by their respective proportions in the company's capital structure.

Here is how we calculate WACC for China Resources Boya Bio pharmaceutical Group Co Ltd

WACC
6.52%
=
Cost of Equity
6.53%
x
Equity Weight
100%
+
Cost of Debt
5%
x
Debt Weight
0%
Back to Top